Resistance to proteasome inhibitors in cancer : molecular mechanisms and strategies to overcome resistance / Q. Ping Dou, editor.
The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases,...
Saved in:
| Online Access: |
Full Text (via Springer) |
|---|---|
| Other Authors: | |
| Format: | eBook |
| Language: | English |
| Published: |
Cham :
Springer,
[2014]
|
| Series: | Resistance to targeted anti-cancer therapeutics.
|
| Subjects: |
Table of Contents:
- Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer
- Resistance to proteasome inhibitors in multiple myeloma
- Overcoming bortezomib resistance: a review on the second generation proteasome inhibitor carfilzomib in the treatment of multiple myeloma
- Proteasome inhibitors in the treatment of multiple myeloma and amyloidosis
- Profiling bortezomib resistance in multiple myeloma: implications in personalized pharmacotherapy
- Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition
- Pre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies
- Overcoming inherent resistance to proteasome inhibitors in head and neck cancer: Challenges and new approaches
- Targeting the proteasome pathway for the treatment of solid tumors
- Oxidative stress and the proteasome: mechanism and the therapeutic relevance
- Proteotoxic stress and proteasome inhibitor efficacy and resistance
- Proteasome inhibitors versus E3 ligase inhibitors for cancer therapy
- Novel ubiquitin E3 ligases as targets for cancer therapy: Focus on breast cancer associated gene 2 (BCA2)
- The 26S proteasomal ATPases: structure, function, regulation and potential for cancer therapies
- Deubiquitinating enzymes as novel targets for cancer therapies.